300 Thousand compounds in stock
Original and unique
Make-on-demand
Building Blocks
1B novel building blocks
Reliable supply
Over 650 highly skillful chemists
Unique synthesis technologies
48B Billion
REAL compounds and
Custom Library Synthesis
On site access to all Enamine stock BB’s
Highly flexible arrangements
2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from February 2024
Recent News
27 March 2024
Press Release
March, 2024, Kyiv, Ukraine. Enamine Ltd, the global leader in supplying small molecules and early drug discovery services, announces the expansion of its library synthesis capabilities with a focus on Enamine REAL compounds to further support the growing demands of agricultural and pharmaceutical companies, research institutes, and drug discovery centers.
01 March 2024
News
We are excited to announce a strategic collaboration between Enamine, the world's leading provider of chemical building blocks, compound libraries, and biology services, and Genez International, a prominent enterprise with 15 years of experience in cross-border supply management, biopharmaceutical research and development, semiconductor equipment, and high-definition digital imaging systems.
21 February 2024
Press Release
Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative new solutions for the early drug discovery process.
Acta Naturae , 2013, 5 (2), 90-99
DOI: PMC3695357
Moriev R.; Vasylchenko O.; Platonov M.; Grygorenko O.; Volkova K.; Zozulya S.
The aim of this study was to identify small molecule compounds that inhibit the kinase activity of the IGF1 receptor and represent novel chemical scaffolds, which can be potentially exploited to develop drug candidates that are superior to the existing experimental anti-IGF1R therapeuticals. To this end, targeted compound libraries were produced by virtual screening using molecular modeling and docking strategies, as well as the ligand-based pharmacophore model. High-throughput screening of the resulting compound sets in a biochemical kinase inhibition assay allowed us to identify several novel chemotypes that represent attractive starting points for the development of advanced IGF1R inhibitory compounds.
Moriev R.; Vasylchenko O.; Platonov M.; Grygorenko O.; Volkova K.; Zozulya S.
Acta Naturae 2013, 5 (2), 90-99
PMC3695357